NOVEL IRON BIOMARKERS IN CHRONIC KIDNEY DISEASE

Area of Science:

• Nephrology
• Hematology
• Biochemistry

Background:

• Chronic kidney disease (CKD) is a rapidly growing cause of death globally, projected to be a top five cause by 2040.
• Anemia is a common and significant clinical complication of CKD, often resulting from reduced erythropoietin production or iron deficiency.
• Iron deficiency anemia in CKD patients is linked to increased mortality and complicates treatment with erythropoiesis-stimulating agents (ESA) and iron substitution.

Purpose of the Study:

• To review the challenges in diagnosing iron deficiency anemia in CKD patients.
• To discuss novel biomarkers of iron metabolism for improved clinical relevance.
• To highlight the importance of accurate iron level determination for effective anemia management in CKD.

Main Methods:

• Literature review of current diagnostic methods for iron deficiency anemia in CKD.
• Exploration of novel biomarkers for iron metabolism, including hypoxia-inducible factor, erythroferon, and growth differentiation factor 15.
• Analysis of the clinical relevance and predictive ability of these novel biomarkers.

Main Results:

• Traditional serum iron markers (ferritin, transferrin saturation) have limited predictive ability in CKD.
• Diagnosis can be complicated by the need for more invasive methods like bone marrow iron stores.
• Novel biomarkers show potential for more accurate assessment of iron status in CKD patients.

Conclusions:

• Accurate diagnosis of iron deficiency anemia is crucial for managing CKD complications.
• Novel biomarkers offer promising alternatives to traditional markers for assessing iron metabolism in CKD.
• Further research into these biomarkers could lead to improved treatment strategies and patient outcomes for CKD-related anemia.